The stock of SELLAS Life Sciences Group Inc. (NASDAQ:SLS) last traded at $3.38, down -2.03% from the previous session.
Data from the available sources indicates that SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is covered by 4 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $12.00 and a low of $4.00, we find $8.00. Given the previous closing price of $3.45, this indicates a potential upside of 131.88 percent. SLS stock price is now 26.19% away from the 50-day moving average and 19.92% away from the 200-day moving average. The market capitalization of the company currently stands at $64.29M.
In total, 0 analysts have assigned it a hold rating, and 4 have given it a buy rating. Brokers who have rated the stock have averaged $8.00 as their price target over the next twelve months.
With the price target of $18, Cantor Fitzgerald recently initiated with Overweight rating for SELLAS Life Sciences Group Inc. (NASDAQ: SLS)., while ‘H.C. Wainwright’ rates the stock as ‘Buy’.
In other news, Stergiou Angelos M., President and CEO sold 6,494 shares of the company’s stock on Dec 05. The stock was sold for $16,938 at an average price of $2.61. Upon completion of the transaction, the President and CEO now directly owns 161,689 shares in the company, valued at $0.55 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 05, EVP, Gen. Counsel, Corp. Sec. WOOD BARBARA A sold 2,153 shares of the business’s stock. A total of $5,576 was realized by selling the stock at an average price of $2.59. This leaves the insider owning 56,344 shares of the company worth $0.19 million. Insiders disposed of 9,806 shares of company stock worth roughly $33144.28 over the past 1 year. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SLS stock. A new stake in SELLAS Life Sciences Group Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $84,000. OPUS CAPITAL GROUP, LLC invested $66,000 in shares of SLS during the first quarter. In the first quarter, CHARLES SCHWAB INVESTMENT MANAGEMENT INC acquired a new stake in SELLAS Life Sciences Group Inc. valued at approximately $55,000. CWM, LLC acquired a new stake in SLS for approximately $7,000. UBS GROUP AG purchased a new stake in SLS valued at around $5,000 in the second quarter. In total, there are 34 active investors with 10.60% ownership of the company’s stock.
With an opening price of $3.4200 on Tuesday morning, SELLAS Life Sciences Group Inc. (NASDAQ: SLS) set off the trading day. During the past 12 months, SELLAS Life Sciences Group Inc. has had a low of $1.77 and a high of $7.40. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.80, and a quick ratio of 1.80. The fifty day moving average price for SLS is $2.6786 and a two-hundred day moving average price translates $2.8187 for the stock.
The latest earnings results from SELLAS Life Sciences Group Inc. (NASDAQ: SLS) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.41, missing analysts’ expectations of -$0.35 by -0.06. This compares to -$0.45 EPS in the same period last year.
SELLAS Life Sciences Group Inc.(SLS) Company Profile
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.